Tag: ALS (Lou Gehrig’s Disease)
Stakes Are High Ahead of FDA Panel Vote on ALS Drug
AMX0035 is a combination of two established drug ingredients -- sodium phenylbutyrate and taurursodiol
Professional Football Players at Higher Risk for ALS
Risk for incidence, mortality from amyotrophic lateral sclerosis nearly fourfold higher for NFL players compared with the U.S. male population
Lifetime Physical Activity Not Linked to Risk for ALS
Heavy occupational work intensity may increase ALS risk; survival in newly diagnosed ALS patients worse with inactivity, highest activity level
New Gene Variants Identified That May Raise Risk for ALS
Mutations identified in TP73 in ALS patients; mutations caused abnormal differentiation, apoptosis in myoblast differentiation assay
Investigational Drug May Prolong Survival in Patients With ALS
Median survival 6.5 months longer with initiation of PB-TURSO treatment compared with placebo
Sodium Phenylbutyrate-Taurursodiol Promising for ALS
Slower functional decline seen with active drug versus placebo through 24 weeks
High BMI, Weight Gain Linked to Lasting Decrease in ALS Risk
Link found between high BMI, weight gain and lower risk for amyotrophic lateral sclerosis decades later
American Academy of Neurology, May 4-10
The 71st Annual Meeting of the American Academy of Neurology The annual meeting of the American Academy of Neurology was held from May...
AAN: Professional Soccer Players Show Increased Risk for ALS
Median age of diagnosis 43.3 years in soccer players versus 62.5 years in general population
CDC: U.S. Prevalence of ALS Was 5.2 Per 100,000 in 2015
Total of 16,583 cases identified in 2015 using National Amyotrophic Lateral Sclerosis Registry
